Somatostatin analogue scintigraphy in carcinoid tumours

Abstract

PATIENTS AND METHODS PatientsWe studied five patients with Merkel cell tumors in whom iodine 123 (123I)-or indium 111 (mIn)-labeled octreotide scin¬ tigraphy was performed. Histologie confirmation of the lesion was obtained in every patient. All patients gave informed consent to participate in the study, which was approved by the ethics committee of our hospital.

Imaging of gastroenteropancreatic neuroendocrine tumors

“…Gamma-based SRS (Octreoscan ® ) has proved to be a safe, sensitive imaging agent in the detection of GEP NETs, with an overall sensitivity of approximately 80%-90% in patients with gastrointestinal neuroendocrine neoplasms [51][52][53][54] . However, limitations include false negative results in organs with significant physiological uptake (e.g.…”

Acromegaly and Gigantism

“…The measurement of plasma GHRH concentrations can be very helpful in identifying an ectopic source of GHRH in these particular cases. Total body scintigraphy with radiolabled somatostatin should be performed to localize the tumor and to demonstrate somatostatin receptor expression by the tumor which may respond favorably to somatostatin analogue therapy (Kwekkeboom et al, 1993;Drange et al, 1998).…”

Consensus Recommendations for the Diagnosis and Management of Well-Differentiated Gastroenterohepatic Neuroendocrine Tumours: A Revised Statement from a Canadian National Expert Group

“…Scintigraphy using 111 In-pentetreotide can detect octreotide-avid lesions throughout the body, and therefore can assist in disease staging, preoperative evaluation, surveillance, and monitoring response to therapeutic intervention 52 . Available data also suggest that somatostatin-avid disease on scintigraphy may imply a preferential benefit in disease control with therapeutic doses of octreotide (discussed later in this article), although long-term data are lacking [53][54][55][56] .…”